Eton Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Eton Pharmaceuticals

13/08/2026 22:01

Eton Pharmaceuticals Inc ETON.OQ reported quarterly adjusted earnings of 35 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -10 cents.  The mean expectation of four analysts for the quarter was for earnings of 11 cents per share. Wall Street expected results to range from 10 cents to 11 cents per share.
Revenue rose 98.6% to $37.59 million from a year ago; analysts expected $27.12 million. 
Eton Pharmaceuticals Inc's reported EPS for the quarter was 35 cents​.
The company reported quarterly net income of $11.58 million.
Eton Pharmaceuticals Inc shares had risen by 14.9% this quarter and gained 145.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 28.4% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $61.00, about 31.8% above its last closing price of $41.58
This summary was machine generated from LSEG data August 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.11
0.35
Beat
Mar. 31 2026 
0.09
0.05
Missed
Dec. 31 2025 
0.09
0.06
Missed
Sep. 30 2025 
0.09
-0.07
Missed